Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | TDO2 | P48775 | 2/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.40 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL57488 | 1.00 | IDO1 (0.43) | IDO1TDO2AOC3TRPA1DPP4 | |
| SCHEMBL3855923 | 1.00 | IDO1 (0.43) | IDO1TDO2AOC3TRPA1DPP4 | |
| Hydrochloric Acid SCHEMBL1439116 | 0.98 | IDO1 (0.45) | IDO1TDO2AOC3TRPA1DPP4 | |
| Hydrochloric Acid SCHEMBL1439114 | 0.98 | IDO1 (0.45) | IDO1TDO2AOC3TRPA1DPP4 | |
| Formic Acid SCHEMBL27883524 | 0.90 | GABBR2 (0.39) | IDO1TDO2AOC3TRPA1DPP4 | |
| SCHEMBL1444985 | 0.87 | ANPEP (0.41) | — | |
| Trifluoroacetic Acid SCHEMBL9299736 | 0.85 | DPP4 (0.47) | DPP4DPP8 | |
| SCHEMBL971562 | 0.82 | IDO1 (0.40) | IDO1TDO2AOC3TRPA1DPP4 | |
| SCHEMBL3338459 | 0.82 | IDO1 (0.40) | IDO1TDO2AOC3TRPA1DPP4 | |
| SCHEMBL30059303 | 0.82 | IDO1 (0.40) | IDO1TDO2AOC3TRPA1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206751-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC. (JP) | 2025-06-26 | — | — | US | disclosed |
| EP-4491624-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | Astellas Pharma Inc. (JP) | 2025-01-15 | — | — | EP | disclosed |
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2024-05-30 | — | — | US | disclosed |
| WO-2024034657-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HETEROCYCLIC COMPOUND | アステラス製薬株式会社 | 2024-02-15 | — | — | WO | disclosed |
| WO-2024034123-A1 | PHARMACEUTICAL COMPOSITION CONTAINING HETEROCYCLIC COMPOUND | アステラス製薬株式会社 | 2024-02-15 | — | — | WO | disclosed |
| EP-4288412-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | Rappta Therapeutics Oy (FI) | 2023-12-13 | — | — | EP | disclosed |
| CN-116829726-A | Biological production of enantiomerically pure (R) -and (S) -2-phenylglycinol from styrene and renewable raw materials by artificial enzyme cascade | 新加坡国立大学 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023171781-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | アステラス製薬株式会社 | 2023-09-14 | — | — | WO | disclosed |
| WO-2022167866-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2022-08-11 | — | — | WO | disclosed |
| WO-2021071843-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | Pipeline Therapeutics, Inc. (US) | 2021-04-15 | — | — | WO | disclosed |
| US-5952369-A | ANALGESIC, TREATMENT FOR STROKE OR ABDOMINAL PAIN ASSOCIATED WITH FUNCTIONAL BOWEL DISEASE | PFIZER INC (US) | 1999-09-14 | — | — | US | disclosed |
| US-5854268-A | Azetidine, pyrrolidine and piperidine derivatives | MERCK SHARP & DOHME, LTD. (GB) | 1998-12-29 | — | — | US | disclosed |
| US-5814648-A | N-hydroxyureas as antiinflammatory agents | PFIZER INC. (US) | 1998-09-29 | — | — | US | disclosed |
| EP-0861244-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1998-09-02 | — | — | EP | disclosed |
| CN-1191531-A | N-hydroxyureas as antiinflammatory agents | PFIZER (US) | 1998-08-26 | — | — | CN | disclosed |
| CN-1180348-A | Pyrrolidinyl hydroxamic acid compounds and their production process | PFIZER (US) | 1998-04-29 | — | — | CN | disclosed |
| EP-0804434-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1997-11-05 | — | — | EP | disclosed |
| WO-1997018201-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1997-05-22 | — | — | WO | disclosed |
| WO-1996030339-A1 | PYRROLIDINYL HYDROXAMIC ACID COMPOUNDS AND THEIR PRODUCTION PROCESS | PFIZER INC. (US) | 1996-10-03 | — | — | WO | disclosed |
| WO-1996004274-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206751-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | KRAS, NRAS, HRAS | IDO1 3123/4885TDO2 4327/4885AOC3 3231/4885 |
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | PPM1A, PPP2CA, PPP3CA | IDO1 1178/4885TDO2 3246/4885AOC3 3025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.